Biosimilars
Page 1 • 12 itemsTrack global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Biosimilars Growth in Brazil: Market Potential Post-ANVISA Regulatory Updates
This article delves into the market potential for biosimilars in Brazil following recent ANVISA regulatory updates, highlighting Infliximab's role in treating autoimmune conditions.
Biosimilars Market Analysis: Impact of Recent FDA Approvals on US Pricing & Competition
This article analyzes how recent FDA approvals of biosimilars are reshaping pricing dynamics and competition in the US pharmaceutical market.
Biosimilars Market Analysis: US Landscape Post-Inflation Reduction Act 2026
This article analyzes the evolving landscape of the US biosimilars market for Humira post-Inflation Reduction Act 2026, highlighting key trends and implications.
Rise of Biosimilars in US: FDA Approval Trends & Market Impact
The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.
Saudi Arabian Pharmaceutical Market: Impact of SFDA Expedited Drug Approvals
This article examines how the SFDA's expedited drug approvals are transforming the Saudi Arabian pharmaceutical landscape, improving access to essential treatments.
FDA Biosimilar Approval Pathway: Key Regulatory Changes & Market Impact 2026
This article delves into the FDA's regulatory changes for biosimilars, their implications for drug pricing, and the future landscape of patient care in 2026.
SAHPRA Biosimilars Approval: Pathway Analysis & Impact on Affordable Medicines
This article analyzes SAHPRA's biosimilars approval pathway and its significant impact on making affordable medicines like adalimumab accessible for patients.
PANDRH Regulatory Harmonization: What You Need to Know About Biosimilar Market Entry in LATAM
Discover how PANDRH regulatory harmonization impacts biosimilar market entry in LATAM, paving the way for innovative therapies and improved patient access.
US Oncology Biosimilar Landscape 2026: Pricing & Market Access Insights
Delve into the evolving US oncology biosimilar market by 2026, analyzing pricing strategies and market access for critical treatments like Trastuzumab.
Rise of Biosimilars: Market Impact Post-2026 Patent Expirations in US
As key biologics like Herceptin face patent expirations post-2026, the rise of biosimilars is set to transform the US pharmaceutical landscape.
COFEPRIS Biocomparables Pathway: What You Need to Know
Learn about the COFEPRIS Biocomparables pathway, a crucial process for approving biosimilars like Adalimumab, aimed at enhancing treatment accessibility.
Biosimilar Competition Impact: US Biologics Market Analysis 2026
This analysis delves into how biosimilar competition will reshape the US biologics market by 2026, highlighting significant drugs and their therapeutic indications.